Nesfatin-1 is a biomarker that plays a role in the inflammatory process of coronary artery diseases in Iraqi patients with non-alcoholic fatty liver disease.

Amis: NAFLD is considered to be the most common cause of liver conditions worldwide. Also, it is a primary reason that leads to coronary artery diseases, limiting blood flow to the heart. Therefore, This study aimed to evaluate the serum level of Nesfatin-1 and its ability to indicate the prognosis of CAD in patients with NAFLD. Material & Methods: one-hundred eighty Individuals were enrolled in the study, including In both genders, blood was collected from each Individual and sent to the laboratory for biochemical tests. Findings: Data from the current study showed a significant increase in Nesfatin-1 in the CAD group and a significant decrease in Nesfatin-1 in the NAFLD group compared to the control group. In addition, there was also a significant increase in both cardiac parameters and AST in the CAD group compared to the NAFLD group and the control group. Conclusion: Patients with coronary artery disease have higher Nesfatin-1 Concentration due to Nesfatin-1 having anti-inflammatory properties that raise the level of Nesfatin-1. In addition, Data from the current study showed a significant positive correlation between Nesfatin-1 and (ALT and AST) in NAFLD patients. However, further studies are needed to confirm this conclusion. Keywords: Coronary Artery Disease, Non-alcoholic fatty liver disease, Nesfatin1, Troponin-I